General Information of Drug (ID: DMLKF3H)

Drug Name
Prolanta Drug Info
Indication
Disease Entry ICD 11 Status REF
Fallopian tube cancer 2C74 Phase 1 [1]
Ovarian cancer 2C73 Phase 1 [1]
Peritoneal cavity cancer 2C51.Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMLKF3H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Prolactin receptor (PRLR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Endostatin DM8NLDI Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
LFA-102 DMI4O92 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prolactin receptor (PRLR) TTBPXMA PRLR_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721).